Latest news and press releases about Sagimet Biosciences Inc. (SGMT): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company’s lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis, acne, and select forms of cancer.
Price
| Price | $10.46 |
| Market Cap | $341M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 2.17 |
| EV / EBITDA | -3.87 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -31.96% |
| Return on Invested Capital | -20.39% |
| Return on Assets | -17.87% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ACHV · ARCT · ASMB · AVIR · FHTX · HUMA · IMRX
Explore sector: Healthcare · Biotechnology
More sections of SGMT: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks